LumiraDx Gets CE Mark for Point-of-Care SARS-CoV-2, Flu Assay
2021/12/24 12:20:15 Views£º515Original from: 360DX
LumiraDx said on Thursday that it has received CE marking for its point-of-care SARS-CoV-2 & Flu A/B Antigen Test.
The microfluidic immunofluorescence assay is designed for the simultaneous detection and differentiation of SARS-CoV-2, influenza A, and influenza B viral antigen in nasal swab specimens. It runs on the LumiraDx platform and provides results within 12 minutes.
Last month, UK-based LumiraDx ¡ª which went public on the Nasdaq in April ¡ª reported surging third quarter revenues on strong sales of its of test strips for its COVID Ag SARS-CoV-2 antigen test.
Source: LumiraDx Gets CE Mark for Point-of-Care SARS-CoV-2, Flu Assay
- CAIVD WeChat
Subscription Account
- CAIVD WeChat
Channels
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.